Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-T) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin Lin, T. L., Uy, G. L., Wieduwilt, M. J., Newell, L. F., Stuart, R. K., Medeiros, B. C., Schiller, G. J., Rubenstein, S., Stock, W., Warlick, E., Foster, M., Bixby, D. L., Podoltsev, N., An, Q., Faderl, S., Louie, A. C., Lancet, J. E. ELSEVIER SCIENCE INC. 2018: S228–S229

View details for Web of Science ID 000425476000315